Comorbidity - Articles - Page 2

Addiction and Borderline Personality Disorder

July 1, 2022

Ashley Pierson, PhD

Assistant Professor of Psychiatry and acting director of DBT services, General Adult Intensive Outpatient Program, Yale University, New Haven, CT.

Dr. Pierson, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Borderline personality disorder is highly comorbid with substance use disorders for reasons that are described by Dr. Pierson. She also reviews some basics of dialectical behavioral therapy, the gold standard treatment for borderline personality disorder, and shows us how therapeutic principles can be applied the treatment of addiction.

Real-World Alcohol Use Disorder Treatment

March 1, 2022

Ismene Petrakis, MD

Ismene Petrakis, MD

Addiction psychiatrist and professor at Yale School of Medicine. Chief of Mental Health, VA Connecticut Healthcare System, New Haven, CT.

Dr. Petrakis has disclosed that she participated in a study in which she did not receive any compensation from Alkermes apart from medication and Alkermes did not fund the study. Dr. Capurso has reviewed this material and found no evidence of bias pertaining to this educational activity.

Many patient with alcohol use disorder (AUD) also have comorbid psychiatric illness. Treating these patients can be challenging however there are evidenced based approaches that have been shown to be effective. Dr. Petrakis reviews the latest evidence in treating AUD in this challenging population.

Using Smoking Cessation Medications in Patients With Mental Illness

January 18, 2022

Michael Weaver, MD, FASAM.

Michael Weaver, MD, FASAM. Professor and medical director at the Center for Neurobehavioral Research on Addictions at the University of Texas Medical School. Dr. Weaver has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Helping patients with mental illness quit smoking can be particularly challenging; however, there are evidenced based strategies that can help. In this article, we review the evidence for smoking cessation medications in patients with mental illness and highlight some important special considerations.

How to Treat ADHD in Bipolar Disorder

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.

EXPERT Q&A

The Schizophrenia-OCD Overlap

September 28, 2021

Michael Poyurovsky, MD

Michael Poyurovsky, MD

Ma’ale HaCarmel Mental Health Center, Tirat Carmel, Israel; Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. Dr. Poyurovsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

OCD and schizophrenia often overlap, but treatment of this comorbidity is risky terrain. Dr. Poyurovsky explains when antidepressants should be avoided and details which antipsychotics are more likely to exacerbate OCD and which ones are more likely to help it.

How to Diagnose ADHD in Bipolar Disorder

September 28, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Most patients with bipolar disorder have cognitive complaints, but it’s a mistake to diagnose them all with ADHD, and a mistake to miss the genuine ADHD-bipolar comorbidity as well. Inside, a step-by-step guide to teasing apart the diagnoses.

RESEARCH UPDATE

Omega-3s and Metabolic Risks in Schizophrenia

September 28, 2021

Batya Swift Yasgur, MA, LSW, and Chris Aiken, MD.

Batya Swift Yasgur, MA, LSW, and Chris Aiken, MD. The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Omega-3s are helpful for negative symptoms in schizophrenia, and this study suggests they may have metabolic benefits as well.

CLINICAL UPDATE

Depression, Vitamin D, and COVID-19

May 4, 2021

Paul Riordan, MD.

Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University. Dr. Riordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Vitamin D deficiency is causing everything from depression to cancer to COVID-19, at least that’s what our patients are hearing. Paul Riordan looks at the strength of that research and clarifies when to check levels and when to supplement.

EXPERT Q&A

Opioid Use Disorders and Serious Mental Illness

December 10, 2020

Sandra Gomez-Luna, MD

Sandra Gomez-Luna, MD
Clinical Assistant Professor at Yale University. Adult, adolescent, and child psychiatrist in Darien, CT. Dr. Gomez-Luna has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Those with serious mental illness and unhealthy opioid use have special treatment considerations due to polypharmacy and overlapping stigma. Dr. Gomez-Luna walks us through these nuances and explains microdosing of buprenorphine—a helpful technique for starting treatment in patients who may have other opioids on board.

Does Low to Moderate Alcohol Drinking Help or Hurt Cognition?

December 10, 2020

Deepti Anbarasan, MD.

Deepti Anbarasan, MD. Dr. Anbarasan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We’re often presented with mixed messages regarding mild or moderate alcohol consumption and its effect on brain and/or cardiovascular health. This current study tracks alcohol consumption and its effects on cognition performance among middle-aged and older adults in the U.S.